Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

Harbour BioMed has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb focused on discovering and developing next-generation multi-specific antibodies for immunology and oncology.1 2 3

Under the deal, Bristol Myers Squibb will provide $90 million in total potential payments upfront and near term, with additional development and commercial milestones of up to $1.035 billion, plus tiered royalties if BMS advances all programs.1 3 5

The collaboration will leverage Harbour BioMed’s Harbour Mice fully human antibody technology platform to enable efficient discovery and development of multispecific biologics.1 3

Harbour BioMed will work alongside BMS to advance and accelerate multi-specific antibody discovery programs, with the option to use Harbour’s capabilities to run early clinical trials in China.1 2 3

The overall deal value is described as a $1B+ ‘biobucks’ antibody alliance, reflecting the combination of upfront, milestone, and potential royalty payments.3 4 5

Sources:

1. https://www.harbourbiomed.com/news/253.html

2. https://www.pharmaceutical-technology.com/news/harbour-biomed-bms/

3. https://www.pharmexec.com/view/roundup-harbor-biomed-announces-collaboration-license-agreement-with-bristol-myers-squibb-vyne-therapeutics-enters-merger-agreement-with-yarrow-bioscience

4. https://insights.citeline.com/scrip/business/deals/bms-jumps-aboard-harbours-rd-ship-R7NL6JHJERFCVLJDB2HDRVTT5M/

5. https://www.biospace.com/deals/bms-forges-1b-antibody-alliance-with-chinese-firm-harbour

Sources:

Leave a Reply Cancel reply